Dana Emad Eddin Obaid

Dana Emad Eddin Obaid

Auto-generated profile, based on publicly available information

Dana Emad Eddin Obaid

College of Pharmacy, Al Ain University of Science and Technology, Al Ain, United Arab Emirates

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Current Computer-Aided Drug Design
Verified
Journal Article
Closed access
PDF file
IBIlham Boulhissa
Ilham Boulhissa
ACAbdelouahab Chikhi
Abdelouahab Chikhi
ABAbderrahmane Bensegueni
Abderrahmane Bensegueni
MGMohammad Ahmad Ghattas
Mohammad Ahmad Ghattas
EMEl Hassen Mokrani
El Hassen Mokrani
DODana Emad Eddin Obaid
Dana Emad Eddin Obaid
Background: Considering the interesting role in the peptidoglycan biosynthesis pathway, the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase is an attractive target to develop new antibacterial agents. It catalyzes the first key step of this pathway and its inhibition leads to bacterial cell death. Fosfomycin is known as the natural inhibitor of MurA. Objective: The study aimed to introduce new inhibitors of MurA by virtual screening of different chemical compounds libraries, and test the best scored “virtual hits” against three pathogenic bacteria: Escherichia coli, Bacillus subtilis and Staphylococcus aureus. Methods: A virtual screening of the structural analogues of fosfomycin downloaded from the Pub- Chem database was performed. Moreover, French National Chemical Library and ZINC database were also utilized to identify new structures different from fosfomycin. FlexX was the software used for this study. The antibacterial testing was divided into two methods: disk diffusion and broth dilution. Results: A set of virtual hits was found to have better energy score than that of fosfomycin, seven of them were tested in vitro. In addition, the disk diffusion method explored four compounds that exhibited antibacterial activity: CID-21680357 (fosfomycin analogue), AB-00005001, ZINC04658565, and ZINC901335. The testing was continued by broth dilution method for both compounds CID-21680357 and ZINC901335 to determine their minimum inhibitory concentrations, and ZINC901335 had the best value with 457μg/ml against Staphylococcus aureus. Conclusion: Four compounds were found and proven in silico and in vitro to have antibacterial activity: CID-21680357, AB-00005001, ZINC04658565, and ZINC901335.